Survivin and epidermal growth factor receptor expression in surgically treated oropharyngeal squamous cell carcinoma

Head and Neck

Volumn 30, Issue 10, 2008, Pages 1318-1324

  Preuss, Simon Florian ^a   Weinell, Antje ^a   Molitor, Markus ^a   Semrau, Robert ^a   Stenner, Markus ^a   Drebber, Uta ^a   Wedemeyer, Inga ^a   Hoffmann, Thomas K ^b   Guntinas Lichius, Orlando ^c   Klussmann, Jens Peter ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

EGFR; Multimodal treatment; Oropharyngeal squamous cell carcinoma; Survivin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; SURVIVIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYSTEINE PROTEINASE INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; OROPHARYNGEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 55549111870     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20876     Document Type: Article

References (40)

1. Santini J, Formento JL, Francoual M, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991;13:132-139.
2. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873-1878.
3. Reuter CW, Morgan MA, Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 2007;96:408-416.
4. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
5. Li F, Ling X. Survivin study: an update of "what is the next wave"? J Cell Physiol 2006;208:476-486.
6. Li F. Survivin study: what is the next wave? J Cell Physiol 2003;197:8-29.
7. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-8589.
8. Altieri DC. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 2003;5:447-452.
9. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001;108:981-990.
10. Lo Muzio L, Farina A, Rubini C, et al. Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett 2005;225:27-33.
11. Lin CY, Hung HC, Kuo RC, Chiang CP, Kuo MY. Survivin expression predicts poorer prognosis in patients with areca quid chewing-related oral squamous cell carcinoma in Taiwan. Oral Oncol 2005;41:645-654.
12. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003;88: 115-119.
13. Kajiwara Y, Yamasaki F, Hama S, et al. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 2003;97:1077-1083.
14. Andersen MH, Thor SP. Survivin: a universal tumor antigen. Histol Histopathol 2002;17:669-675.
15. Korkola JE, DeVries S, Fridlyand J, et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003;63: 7167-7175.
16. Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol 2004;17:1378-1385.
17. Ferrandina G, Legge F, Martinelli E, et al. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer 2005;92:271-277.
18. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277:3247-3257.
19. Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002;21:2613-2622.
20. Formby B, Wiley TS. Bcl-2, survivin and variant CD44v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. Mol Cell Biochem 1999;202:53-61.
21. Pizzoferrato E, Liu Y, Gambotto A, et al. Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Res 2004;64:8381-8388.
22. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 2004;279:40511-40520.
23. Hattori M, Sakamoto H, Satoh K, Yamamoto T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 2001;169:155-164.
24. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003;362:205-209.
25. Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S, Cerni C. Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene 2003;22:4266-4280.
26. Singh M, Bleile MJ, Shroyer AL, Heinz D, Jarboe EA, Shroyer KR. Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Appl Immunohistochem Mol Morphol 2004;12:296-304.
27. Asanuma H, Torigoe T, Kamiguchi K, et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 2005;65:11018-11025.
28. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007;120:1731-1738.
29. Preuss SF, Dinh V, Klussmann JP, Semrau R, Mueller RP, Guntinas-Lichius O. Outcome of multimodal treatment for oropharyngeal carcinoma: a single institution experience. Oral Oncol 2007;43:402-407.
30. Preuss SF, Weinell A, Molitor M, et al. Nuclear survivin expression is associated with HPV-independent carcinogenesis and is a negative prognostic marker in oropharyngeal squamous cell carcinoma. Br J Cancer 2008;98:627-632.
31. Lo Muzio L, Pannone G, Staibano S, et al. Survivin expression in oral squamous cell carcinoma. Br J Cancer 2003;89:2244-2248.
32. Hitt R, Echarri MJ. Molecular biology in head and neck cancer. Clin Transl Oncol 2006;8:776-779.
33. Wang Q, Greene MI. EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway. Exp Mol Pathol 2005;79:100-107.
34. Laimer K, Spizzo G, Gastl G, et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol 2007;43:193-198.
35. Smilek P, Dusek L, Vesely K, Rottenberg J, Kostrica RB. Correlation of expression of Ki-67, EGFR, c-erbB-2, MMP-9, p53, bcl-2, CD34 and cell cycle analysis with survival in head and neck squamous cell cancer. J Exp Clin Cancer Res 2006;25:549-555.
36. Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP, Hallahan DE. Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 2004;91:537-540.
37. Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G. Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol 2004;15:1654-1660.
38. Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005;114:509-512.
39. Engels K, Knauer SK, Metzler D, et al. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol 2007;211:532-540.
40. Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene 2000;19:3225-3234.